ClinicalTrials.gg
CompletedNCT03320616Updated Mar 5, 2018

EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection

A Phase 1 interventional study of EYP001a in Hepatitis B, Chronic, sponsored by Enyo Pharma. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-03-05.

Sponsored by Enyo Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Feb 2017, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Hepatitis B, Chronic with a site in Netherlands — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · Netherlands.

Enrollment
15th of 16
11 · median 117
Started
2017
with 1 other
Phase 1
3 of 19
none open now
Registered
16th of 19
by date
Lead sponsor
2 of 19
Enyo Pharma

Among the 19 studies in Hepatitis B, Chronic with a site in Netherlands, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2017, is one of 3 in phase 1, and was the 16th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 19 studies in Hepatitis B, Chronic with a site in Netherlands is open now. Recruiting first, the newest first:

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hepatitis B, Chronic with a site in Netherlands, or all of them as a file.
02

Study summary

The farnesoid X receptor (FXR) regulates hepatitis B virus replication through the bile acids pathway. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B.

This Phase 1 study is designed primarily to assess Pharmacokinetics (PK) under fed and fasted conditions, and to assess the safety, tolerability and Pharmacodynamics (PD) of single oral doses of EYP001a in subjects with chronic HBV infection.

Read the detailed description

This is a single-center, open-label, randomized, 4-way crossover study.

A total of 14 chronic HBV subjects will participate. Subjects will receive 4 single dose administrations of EYP001a during the study. There will be 2 separate dosing periods: 1 period with 2 single administrations of EYP001a in the morning, once under fasted conditions and once under fed condition (separated by 48.5 hours), and 1 period with 2 single administrations of EYP001a in the evening, once under fasted conditions and once under fed condition (separated by 48.5 hours).

The subjects will be randomized to 1 of 4 treatment sequences:

  • Sequence 1: Period 1 first dose morning fasted, second dose morning fed; Period 2 first dose evening fasted, second dose evening fed.
  • Sequence 2: Period 1 first dose evening fasted, second dose evening fed; Period 2 first dose morning fasted, second dose morning fed.
  • Sequence 3: Period 1 first dose morning fed, second dose morning fasted; Period 2 first dose evening fed, second dose evening fasted.
  • Sequence 4: Period 1 first dose evening fed, second dose evening fasted; Period 2 first dose morning fed, second dose morning fasted.

Participation will include an eligibility screening period of maximally 40 days, clinic stay during the treatment periods, and a followup visit 4 to 6 days after the last study drug administration.

The safety and tolerability of EYP001a will be assessed by evaluating vital signs, ECGs, liver ultrasound, clinical laboratory and adverse events.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has given voluntary written before performance of any study related procedure
  2. Has documented chronic infection (documented within 12 months of screening visit), with criteria at screening: hepatitis B surface antigen (HBsAg) ≥ 50 IU/mL; HBV DNA > 100 IU/mL; hepatitis Be antigen (HBeAg) negative or positive
  3. Gender: male or female
  4. Age: 18-65 years, inclusive, at screening
  5. (BMI): 17.0-35.0 kg/m2 inclusive, at screening
  6. Weight: >60 kg for males and >45 kg for females
  7. Has clinical chemistry, hematology, coagulation and urinalysis tests within normal, allowable limits (with the exception of (ALAT) [see inclusion criterion #10]); if there is an out of range value, it must be considered clinically insignificant in order to be eligible
  8. Has normal vital signs after at least 5 minutes resting in supine position at screening: 95 mm Hg \< systolic blood pressure \< 140 mm Hg; 45 mm Hg \< diastolic blood pressure \< 90 mm Hg; 40 bpm \< heart rate \< 90 bpm
  9. Has no abnormal 12-lead automatic (ECG) (incomplete right bundle branch block can be accepted) at screening: 120 ms \< PR-interval \< 210 ms, QRS-duration \< 120 ms, interval (QTc) (Fridericia's) ≤ 450 msec for males and females
  10. Has ALAT ≤ 3 x (ULN) at screening
  11. Has documented liver histology with Metavir score (F0, F1, F2 or F3) or liver fibrosis documented with non-invasive alternatives to liver (Fibroscan) or shear wave elastography (Aixplorer) value \< 14.6 kPa
  12. Agrees to abstain from all medication, including non-prescription and prescription medication (including vitamins and natural or herbal remedies, e.g. St. John's Wort) for 28 days prior to (each) admission to the clinical research center until discharge, except for authorized medications such as hormonal for females (registered in The Netherlands) and paracetamol. On a case-by-case basis, regular co-medication either as defined on the separate medication exception list or as documented by written approval from the Sponsor and the PI as acceptable prior to randomization, will not be considered as a deviation from this criterion. All other situations related to co-medications are considered as deviations
  13. At screening, females must be non-pregnant and non-lactating, or of non- (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1 year [amenorrhoea duration of 12 consecutive months); non-pregnancy will be confirmed for all females by a serum pregnancy test conducted at screening and at (each) admission to the clinical research center
  14. Female subjects of child-bearing potential, with a fertile male sexual partner, should be willing to use adequate contraception from screening until 90 days after the followup visit. Adequate contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the subject, is acceptable
  15. Male subjects, if not surgically sterilized, should be willing to use adequate contraception and not donate sperm from (first) admission to the clinical research center until 90 days after the follow-up visit. Adequate contraception for the male subject (and his female partner) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the subject is acceptable
  16. At screening, has no recent (\<3 months) history of any clinically significant conditions, which, in the opinion of the PI, would jeopardize the safety of the subject or impact the validity of the study results
  17. Willingness to abstain from alcohol and methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, energy drinks) from 48 hours prior to (each) admission to the clinical research center

Exclusion criteria

Exclusion Criteria:

  1. Previous participation in the current study
  2. Employee of PRA or the Sponsor
  3. Currently receives or has received during the 60 days (or 5 half-lives of the specific drug, whichever is longer) before (first) admission to the clinical research center until (the last) discharge a nucleos(t)ide-analogue therapy or other anti treatment (interferons, experimental anti HBV drugs or vaccines)
  4. Coinfection with virus (HCV), hepatitis D virus (HDV) or (HIV)
  5. Receives or plans to receive systemic medications during the study or ≤2 months prior to the first study drug administration
  6. Receiving or planning to receive interferon (IFN) during the study or ≤12 months prior to the first study drug administration
  7. Has significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia
  8. Clinical diagnosis of substance abuse with alcohol (regular alcohol consumption >21 units [men] and >14 units [women] per week [1 unit = ½ pint of beer, 25 mL shot of 40% spirit or a 125 mL glass of wine]), narcotics, or cocaine ≤12 months prior to screening
  9. Has any known pre-existing medical or psychiatric condition that could interfere with the subject's ability to provide or participate in study conduct, or that may confound study findings.
  10. Has a history of gastrointestinal disease, especially peptic ulcerations, gastrointestinal bleeding, ulcerative colitis, cholecystectomy, Crohn's disease or Irritable Bowel Syndrome, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, or cardiovascular disease or any other condition which, in the opinion of the PI, would jeopardize the safety of the subject or impact the validity of the study results
  11. Has had acute diarrhea or constipation in the 7 days before (first) admission to the clinical research center. Diarrhea will be defined as the passage of liquid feces and/or a stool frequency of > 3 times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day.
  12. Has a history of long syndrome
  13. Has participated in a drug study within 30 days prior to the first drug administration in the current study
  14. Has a positive drug and alcohol screen (opiates, methadone, cocaine, methamphetamines, amphetamines, ecstasy, barbiturates, benzodiazepines, tricyclic antidepressants, phencyclidine and alcohol)
  15. Any current or previous (ie, ≤12 months prior to screening) abuse of drugs such as opiates, cocaine, ecstasy, or intravenous amphetamines. Subjects who admit to occasional use of cannabis will not be excluded as long as they are able to abstain from cannabis when they are in the clinical research center.
  16. Has an uncontrolled current illness (e.g., active infection)
  17. Has had major surgery within 30 days prior to the first drug administration, or 12 months prior to the first drug administration for gastrointestinal surgery
  18. Has lost more than 100 mL of blood within 60 days prior to the first drug administration
  19. Has a history of relevant drug and/or food allergies
  20. Smokes more than 20 cigarettes per day
  21. Non-willingness to consume the Food and Drug Administration (FDA) breakfast
  22. Poor venous accessibility
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Sequence 1

    4 single doses of EYP001a: Period 1 first dose morning fasted, second dose morning fed; Period 2 first dose evening fasted, second dose evening fed

    Drug: EYP001a

  • Experimental
    Sequence 2

    4 single doses of EYP001a: Period 1 first dose evening fasted, second dose evening fed; Period 2 first dose morning fasted, second dose morning fed

    Drug: EYP001a

  • Experimental
    Sequence 3

    4 single doses of EYP001a: Period 1 first dose morning fed, second dose morning fasted; Period 2 first dose evening fed, second dose evening fasted

    Drug: EYP001a

  • Experimental
    Sequence 4

    4 single doses of EYP001a: Period 1 first dose evening fed, second dose evening fasted; Period 2 first dose morning fed, second dose morning fasted

    Drug: EYP001a

Interventions

  • Oral EYP001a capsules - 100 mg strength

06

What researchers measure

Primary outcomes

  1. Type and frequencies of adverse events

    Time frame: Day 1 of Period 1 through Day 7 to Day 9 of Period 2

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of EYP001a

    ng/mL

    Time frame: Predose to 48 hours after dosing

  2. Time to attain maximum observed plasma concentration (Tmax) after EYP001a administration

    h

    Time frame: Predose to 48 hours after dosing

  3. Area under the plasma concentration-time curve (AUC)

    ng\*h/mL

    Time frame: Predose to 48 hours after dosing

  4. Bile acid precursor C4 (7α hydroxy-4-cholesten-3-one)

    ng/mL

    Time frame: Predose to 48 hours after dosing

  5. Bile-regulating fibroblast growth factor 19 (FGF-19)

    pg/mL

    Time frame: Predose to 48 hours after dosing

07

Study locations

1 site
  • PRA-EDS
    Groningen, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Oct 2017, 8 months.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 8 months is below that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2017
First posted
Oct 25, 2017
StartActual
Feb 10, 2017
Primary completionActual
Oct 12, 2017
CompletionActual
Oct 12, 2017
Last update
Mar 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03320616
Lead sponsor
Enyo Pharma
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Oct 25, 2017
Start date
Feb 10, 2017
Primary completion
Oct 12, 2017
Completion
Oct 12, 2017
Last update
Mar 5, 2018

Study contacts

Jeroen van de Wetering, MD
principal investigator · PRA-EDS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EYP001A

Start the discussion